Stockreport

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam [Yahoo! Finance]

Cassava Sciences, Inc.  (SAVA) 
Last cassava sciences, inc. earnings: 8/12 08:30 am Check Earnings Report
PDF Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology [Read more]